Back to Search Start Over

Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension

Authors :
Christopher J. Rhodes
Anna Ulrich
William C. Nichols
Tufik R. Assad
Richard C. Trembath
Martin R. Wilkins
Lars Harbaum
Stefan Gräf
Marc Humbert
David-Alexandre Trégouët
John Wharton
Florent Soubrier
Ankit A. Desai
Nicholas W. Morrell
Inga Prokopenko
Emilia M. Swietlik
Evan L. Brittain
Laura Southgate
Timothy E. Thayer
British Heart Foundation
The Academy of Medical Sciences
Imperial College London
Vanderbilt University Medical Center [Nashville]
Vanderbilt University [Nashville]
University of Cambridge [UK] (CAM)
AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)
Hypertension pulmonaire : physiopathologie et innovation thérapeutique (HPPIT)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay
Cincinnati Children's Hospital Medical Center
Sorbonne Université (SU)
Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP]
Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
St George's, University of London
Bordeaux population health (BPH)
Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
King‘s College London
University of Surrey (UNIS)
Gestionnaire, Hal Sorbonne Université
Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN)
CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Source :
The European Respiratory Journal, European Respiratory Journal, European Respiratory Journal, European Respiratory Society, 2020, 55 (2), pp.1901486. ⟨10.1183/13993003.01486-2019⟩, European Respiratory Journal, 2020, 55 (2), pp.1901486. ⟨10.1183/13993003.01486-2019⟩
Publication Year :
2020

Abstract

Pulmonary arterial hypertension (PAH) is a rare disease that leads to premature death from right heart failure. It is strongly associated with elevated red cell distribution width (RDW), a correlate of several iron status biomarkers. High RDW values can signal early-stage iron deficiency or iron deficiency anaemia. This study investigated whether elevated RDW is causally associated with PAH. A two-sample Mendelian randomisation (MR) approach was applied to investigate whether genetic predisposition to higher levels of RDW increases the odds of developing PAH. Primary and secondary MR analyses were performed using all available genome-wide significant RDW variants (n=179) and five genome-wide significant RDW variants that act via systemic iron status, respectively. We confirmed the observed association between RDW and PAH (OR 1.90, 95% CI 1.80–2.01) in a multicentre case–control study (cases n=642, disease controls n=15 889). The primary MR analysis was adequately powered to detect a causal effect (odds ratio) between 1.25 and 1.52 or greater based on estimates reported in the RDW genome-wide association study or from our own data. There was no evidence for a causal association between RDW and PAH in either the primary (ORcausal 1.07, 95% CI 0.92–1.24) or the secondary (ORcausal 1.09, 95% CI 0.77–1.54) MR analysis. The results suggest that at least some of the observed association of RDW with PAH is secondary to disease progression. Results of iron therapeutic trials in PAH should be interpreted with caution, as any improvements observed may not be mechanistically linked to the development of PAH.<br />Mendelian randomisation using genetic data from the largest-to-date PAH cohort does not support red cell distribution width or iron deficiency as a cause of PAH, which is important when interpreting iron replacement trials in this condition http://bit.ly/2PPaa88

Details

Language :
English
ISSN :
09031936 and 13993003
Database :
OpenAIRE
Journal :
The European Respiratory Journal, European Respiratory Journal, European Respiratory Journal, European Respiratory Society, 2020, 55 (2), pp.1901486. ⟨10.1183/13993003.01486-2019⟩, European Respiratory Journal, 2020, 55 (2), pp.1901486. ⟨10.1183/13993003.01486-2019⟩
Accession number :
edsair.doi.dedup.....3f68215cca1569b0b16cadaf215507e6